ORPHAI
Dead / Abandoned — Abandoned — failure to respond (as of 02 Dec 2024)
What this means for you
This application is over — abandoned 18 Nov 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98203856
- Mark type
- Stylized text
- Filed
- 29 Sept 2023
- Abandoned
- 18 Nov 2024
- Attorney of record
- Susan N. Acquista, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, and genetic diseases; Pharmaceutical and biopharmaceutical agents for the treatment of cancer and rare diseases, namely, Amyotrophic Lateral Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Sarcoidosis, Bronchiolitis Obliterans; Pharmaceutical and biopharmaceutical preparations for the treatment of cancer and rare diseases, namely, Amyotrophic Lateral Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Sarcoidosis, Bronchiolitis Obliterans; Pharmaceutical and biopharmaceutical agents for the treatment of cancer and rare diseases; Pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer and rare diseases; Pharmaceutical, medical, scientific, and biopharmaceutical research and development
- Class 009 — Scientific and electric apparatus: Recorded computer software featuring deep learning algorithms and AI for pharmaceutical, medical, scientific, and biopharmaceutical research and development and analysis, none of the foregoing for design, test and implementation
- Class 042 — Scientific and technological services: Development of pharmaceutical preparations and medicines; Genetic engineering; Laboratory research in the field of gene expression; Medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, and genetic diseases; Medical, pharmaceutical, and biopharmaceutical research services; Non-downloadable computer software featuring deep learning algorithms and AI for pharmaceutical, medical, scientific, and biopharmaceutical research and development and analysis; Pharmaceutical, medical, scientific, and biopharmaceutical research and development; Providing medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, and genetic diseases; Providing research and development relating to pharmaceutical, medical, scientific, and biopharmaceutical; Research in the field of gene therapy; Scientific and medical research in the fields of gene, genome, and genomic editing, modulation, transcription, to develop human pharmaceutical and biopharmaceutical preparations; Scientific research for medical purposes in the field of cancerous diseases; Scientific research in the field of genetics
Owner
- OrphAI Therapeutics Inc., Guilford, CT, US
Prosecution history
- 02 Dec 2024 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 02 Dec 2024 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 14 Aug 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 14 Aug 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 17 May 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 17 May 2024 — NON-FINAL ACTION E-MAILED
- 17 May 2024 — NON-FINAL ACTION WRITTEN
- 07 May 2024 — ASSIGNED TO EXAMINER
- 12 Oct 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 03 Oct 2023 — NEW APPLICATION ENTERED